Abstract
A lack of entrepreneurial behaviour has often been highlighted as a contributor to the decline in the research and development (R&D) productivity of the pharmaceutical industry. Here, we present an assessment of entrepreneurship in the industry, based on interviews with 26 former and current leaders of R&D departments at major pharmaceutical and biotechnology companies. Factors are highlighted that could be important in promoting entrepreneurial behaviour, which might serve as a catalyst for revitalizing R&D productivity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Goodman, M. Pharma industry performance metrics: 2007–2012E. Nature Rev. Drug Discov. 7, 795 (2008).
Pisano, G. P. Science Business: The Promise, the Reality, and the Future of Biotech (Harvard Business School Press, Boston, Massachusetts, USA, 2006).
Cuervo, A., Ribeiro, D. & Roig, S (eds) Entrepreneurship: Concepts, Theory and Perspective (Springer, Berlin, Germany, 2007).
Schramm, C. J. The Entrepreneurial Imperative: How America's Economic Miracle Will Reshape the World (and Change Your Life) (HarperCollins, 2006).
Pharmaceutical Research and Manufacturers of America. PhRMA Annual Membership Survey. PhRMA website [online], (2009).
IMS Health. Global Pharmaceutical Sales, 2001–2008. IMS Health website [online], (2009).
Munos, B. Lessons from 60 years of pharmaceutical innovation. Nature Rev. Drug Discov. 8, 959–968 (2009).
Acknowledgements
With special thanks to D. Kaiser, M. Tribbitt and T. Flores for their research and editorial assistance. We would also like to thank the following colleagues who participated in these interviews: B. Adelman, R. Armstrong, L. Babiss, J. Boger, A. Busch, P. Corr, M. Fishman, T. Glenn, C. Goodman, B. Kirschbaum, J. Leiden, G. Milne, P. Needleman, G. Neil, J. Patterson, S. Paul, J. Reinhardt, P. Ringrose, D. Rosen, L. Rosenberg, R. Ruffolo, V. Sato, B. Shapiro, A. Smith, G. Watanabe and T. Yamada (see Box 1).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors do not believe that any of them have competing financial interests as defined in the Nature journals' competing financial interest policy. However, in the interest of full disclosure, the authors state that Lesa Mitchell and Robert E. Litan are employees of the Ewing Marion Kauffman Foundation which is specifically engaged in research into and the proliferation of concepts relating to entrepreneurship generally. Frank L. Douglas is, among other pursuits, a Senior Fellow of the Ewing Marion Kauffman Foundation and V. K. Narayanan is, among other pursuits, an indirect recipient of grant monies given by the Foundation to Drexel University, Philadelphia, Pennsylvania, USA.
Related links
Rights and permissions
About this article
Cite this article
Douglas, F., Narayanan, V., Mitchell, L. et al. The case for entrepreneurship in R&D in the pharmaceutical industry. Nat Rev Drug Discov 9, 683–689 (2010). https://doi.org/10.1038/nrd3230
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3230
This article is cited by
-
Changing R&D models in research-based pharmaceutical companies
Journal of Translational Medicine (2016)
-
The discovery of first-in-class drugs: origins and evolution
Nature Reviews Drug Discovery (2014)
-
The Paradox of Scientific Excellence and the Search for Productivity in Pharmaceutical Research and Development
Clinical Pharmacology & Therapeutics (2014)
-
Diagnosing the decline in pharmaceutical R&D efficiency
Nature Reviews Drug Discovery (2012)